Connect your AI

ImmunityBio, Inc. IBRX Indefinite Lived Intangible Assets, Gross, Including Goodwill

Other financials

Income statement

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept ibrx:IndefiniteLivedIntangibleAssetsGrossIncludingGoodwill.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s indefinite lived intangible assets, gross, including goodwill.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is ImmunityBio, Inc.'s indefinite lived intangible assets, gross, including goodwill?: ImmunityBio, Inc. (IBRX) reported indefinite lived intangible assets, gross, including goodwill of $972K in Q1 2026.
How has ImmunityBio, Inc.'s indefinite lived intangible assets, gross, including goodwill changed year-over-year?: ImmunityBio, Inc.'s indefinite lived intangible assets, gross, including goodwill decreased by 31.5% year-over-year, from $1.42M to $972K.